Robert C. Doebele - Concepedia

Author

Robert C. Doebele

Also Known As

Amy Wiese, Doebele, R.C., Doebele, Robert C., R C Doebele, R Doebele, R. C. Doebele, R. Doebele, R.C. Doebele, Robert C Doebele, Robert C. Doebele

533

Publications

31.1K

Citations

H-Index

102

Concepts

All Affiliations

University of Colorado Denver University of Colorado Anschutz Medical Campus Memorial Sloan Kettering Cancer Center Massachusetts General Hospital University of Colorado Cancer Center

About

Robert C. Doebele is an author at University of Colorado Denver specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	41	99	9.1K
2	Health Sciences	14	17	1.8K
3	Natural Sciences	5	5	123
4	Engineering	3	3	426
5	Biochemistry	2	2	222

Robert C. Doebele

175

Publications

28.1K

Citations

H-Index

Page 1

	Year	Citations
Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children Alexander Drilon, Theodore W. Laetsch, Shivaani Kummar, New England Journal of Medicine	2018	2.6K
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer Alice T. Shaw, Sai‐Hong Ignatius Ou, Yung‐Jue Bang, New England Journal of Medicine	2014	2K
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials Robert C. Doebele, Alexander Drilon, Luis Paz‐Ares, The Lancet Oncology	2019	1.7K
Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Journal of the National Comprehensive Cancer Network	2017	1.3K
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study Daniel R. Gomez, Chad Tang, Jianjun Zhang, Journal of Clinical Oncology	2019	1.2K
Mechanisms of Resistance to Crizotinib in Patients with <i>ALK</i> Gene Rearranged Non–Small Cell Lung Cancer Robert C. Doebele, Amanda Pilling, Dara L. Aisner, Clinical Cancer Research	2012	1.1K
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study Daniel R. Gomez, George R. Blumenschein, J. Jack Lee, The Lancet Oncology First-line Systemic TherapyMedicineCancer ManagementBronchial NeoplasmCombined Modality Treatment	2016	1.1K
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis Alice T. Shaw, Beow Y. Yeap, Benjamin Solomon, The Lancet Oncology Overall SurvivalAlk Gene RearrangementMedicineRetrospective AnalysisPathology	2011	880
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1) Alexander Drilon, Salvatore Siena, Sai‐Hong Ignatius Ou, Cancer Discovery	2017	795
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing Ashley Maynard, Caroline E. McCoach, Julia Rotow, Cell	2020	666

Page 1